Kura Investors

Investor Home

Corporate Profile
We are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. Our development programs target cancers with high unmet need, including head and neck, lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias.
Recent Newsmore >
07/18/17
Kura Oncology Announces Issuance of U.S. Patent for Lead Product Candidate Tipifarnib in Head and Neck Cancer
07/13/17
Kura Oncology Establishes Collaboration with Foundation Medicine to Support Tipifarnib Development in HRAS Mutant Head and Neck Cancer
06/26/17
Kura Oncology Added to Russell 3000® Index
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Kura Oncology Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.